Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
|Articles|February 28, 2023
- February 2023
- Volume 89
- Issue 2
Pet Peeve: February 2023
Because 1 thing is not enough.
Advertisement
And One More Thing
The “oh, and also....” patient. For example, “Oh, and also can you check if I need a refill on anything?” “Oh, and also can you look up the last time I got this medication?” “Oh, and also I am picking up for another person.”
Articles in this issue
over 3 years ago
Sotyktu From Bristol Myers Squibbover 3 years ago
Interactive Case Studies- February 2023over 3 years ago
OTC Product News: February 2023over 3 years ago
Is It Too Late to Get a Flu Shot?over 3 years ago
Generic Product News February 2023over 3 years ago
March 2023 Rx Product Newsover 3 years ago
Case Study: Shinglesover 3 years ago
Pharmacists Need to Step Up Their Communications Gameover 3 years ago
Pharmacist Files False Claims Act LawsuitAdvertisement
Related to this article
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
4
Sotatercept in ERS PAH Guidelines: What Pharmacists Should Watch
5